Article Information
History
- May 13, 2021.
Article Versions
- You are currently viewing Version 1 of this article (May 13, 2021 - 10:54).
- Version 2 (May 14, 2021 - 09:18).
- View Version 3, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Edward Burn1,2,
- Xintong Li2,
- Kristin Kostka3,4,
- Henry Morgan Stewart3,
- Christian Reich3,
- Sarah Seager3,
- Talita Duarte-Salles1,
- Sergio Fernandez-Bertolin1,
- María Aragón1,
- Carlen Reyes1,
- Eugenia Martinez-Hernandez5,
- Edelmira Marti6,
- Antonella Delmestri2,
- Katia Verhamme7,
- Peter Rijnbeek7 and
- Daniel Prieto-Alhambra2,7,*
- 1Fundació Institut Universitari per a la recerca a l’Atenció Primària de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain
- 2Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDROMS), University of Oxford, UK
- 3Real World Solutions, IQVIA, Cambridge, MA, US
- 4The OHDSI Center at The Roux Institute, Northeastern University, Portland, ME, US
- 5Department of Neurology, Hospital Clinic and University of Barcelona, Barcelona, Spain
- 6Hemostasis and Thrombosis Unit, Hematology Department, Hospital Clínico Universitario de Valencia, Spain
- 7Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands
- ↵*corresponding author Prof Daniel Prieto-Alhambra, Botnar Research Centre, Windmill Road, OX37LD, Oxford, UK, daniel.prietoalhambra{at}ndorms.ox.ac.uk
Posted May 13, 2021.
Background rates of five thrombosis with thrombocytopenia syndromes of special interest for COVID-19 vaccine safety surveillance: incidence between 2017 and 2019 and patient profiles from 20.6 million people in six European countries
